Context: Drug-drug interactions are common but often are discovered only long after initial drug release. Metformin has been available in the United States for 9 yr and elsewhere for many years, but as of yet there are no reports that the drug modifies thyroid hormone economy.
D RUG-DRUG INTERACTIONS are common but often are discovered only long after initial drug release. Metformin has been available in the United States for almost a decade and elsewhere for many more years, but as of yet there are no reports that the drug modifies thyroid hormone economy. We fortuitously observed a reversible metformininduced suppression of TSH, without a change in free T 4 (fT4) or free T 3 (fT3) or clinical signs of hyperthyroidism, in a patient with nonalcoholic steatohepatitis (NASH) who was on l-T 4 after radioactive iodine treatment for Graves' disease. Once the first patient was identified, we identified three additional stable hypothyroid patients (two postsurgical and one with Hashimoto's disease) over approximately a 3-month time span who had also developed TSH suppression when they were placed on metformin for treatment of diabetes mellitus. TKF31; analytical sensitivity 0.31 pmol/liter; intraassay CV 5% at 2.8 pmol/liter; interassay CV 6.8% at 4.7 pmol/liter). Serum TSH was measured by a third-generation chemiluminescence immunoassay (Nichols; TSH-Third Generation, catalog no. 60-4100; analytical sensitivity 0.003 IU/ml; functional sensitivity 0.01 IU/ml; intraassay CV 12.5% at 0.01 IU/ml, 4.6% at 1.28 IU/ml, and 5.1% at 8.35 IU/ml; interassay CV 15.2% at 0.02 IU/ml, 5.8% at 1.22 IU/ml, and 7.3% at 8.52 IU/ml) in patients 1, 2, and 4 or by an electrochemiluminescence immunoassay (Roche Diagnostics; TSH assay kit, catalog no. 11731459122; analytical sensitivity 0.005 IU/ml; functional sensitivity 0.014 IU/ml; intraassay CV 7.2% at 0.04 IU/ml, 3.2% at 0.092 IU/ml, and 3.3% at 9.37 IU/ml; interassay CV 8.7% at 0.034 IU/ml, 3.3% at 0.91 IU/ml, and 3.6% at 3.96 IU/ml) in patient 3. The former assay was used to measure serum the TSH concentration of normal serum to which metformin was added in concentrations from 0.195 to100 g/ml [the therapeutic range of metformin is 0.465-2.5 g/ml (1)].
Patients and Methods

Case reports
Patient 1 is a 58-yr-old nonsmoking, nondrinking Caucasian man who was previously healthy until he developed Graves' disease in 1997. After treatment with 15.6 mCi of radioactive iodine-131, his fT4 fell to 3.8 pmol/liter and TSH rose to 7.67 IU/ml and l-T 4 treatment was initiated and titrated. He remained clinically and biochemically euthyroid on l-T 4 150 g daily for the next 4 yr. In 1998 he developed elevated transaminase levels; a liver biopsy performed in 2001 showed steatosis and fibrosis diagnostic of NASH. Because of increasing serum transaminase levels, metformin XR 1500 mg daily was begun in December 2001. Metformin was continued for the next 8 months until suppression of serum TSH was noted ( Table 1) . At that point, metformin was discontinued, and serum TSH progressively returned to baseline over the next
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JCEM is published monthly by The Endocrine Society (http://www. endo-society.org), the foremost professional society serving the endocrine community. 6 wk. To confirm this presumed relationship between metformin administration and serum TSH suppression, the drug was readministered, with the patient's informed consent, from October 2002 until October 2003 in the same dose as before. Once again, serum TSH suppression was noted, and after discontinuation of metformin and substitution of rosiglitazone (4 mg twice daily), serum TSH rose back into the normal range. During both periods of metformin administration, there were no changes in fT4 or fT3 levels, and there was no weight loss or symptoms consistent with hyperthyroidism. The suppression and recovery of serum TSH was not associated with changes in medications other than metformin. Medication compliance was verified by the patient and confirmed by reviewing refill frequency in the integrated military electronic record.
Patient 2 is a 67-yr-old Caucasian woman who had type 2 diabetes mellitus for 12 yr complicated by mild nephropathy. Treatment of diabetes with neutral protamine Hagedö rn (NPH) (NovoNordisk, Princeton, NJ) and regular insulin taken twice daily resulted in moderate glycemic control (A1c 7.8%). Primary hypothyroidism due to Hashimoto's thyroiditis had been treated with l-T 4 224 g daily, a dose that was stable for 5 yr. Other medical problems include breast cancer stage 1, hypertension, hyperlipidemia, and osteoarthritis. Her other medications were lisinopril, fenofibrate, and aspirin. Metformin XR 500 mg daily was added to her diabetic regimen in October 2002, and 2 months later her serum TSH had fallen from 0.64 IU/ml to a subnormal level of 0.31 IU/ml ( Table 2 ). Increasing the dose of metformin XR to 1000 mg daily led to a further decrease in serum TSH (0.17 IU/ml). Her weight had increased 4 lb while on metformin 500 mg daily but then decreased 3 lb when the drug was increased to 1000 mg daily.
Patient 3 is a 66-yr-old man who had been treated for 4 yr with T 4 125 g daily for hypothyroidism resulting from a thyroidectomy for multinodular goiter. His past medical history includes hypertension, hyperlipidemia, and, since 1998, type 2 diabetes mellitus. His nondiabetic medications were aspirin, lisinopril, simvastatin, amlodipine, and diltiazem. Initial treatment of diabetes with glipizide led to modest glycemic control (A1c 7.2% in June 2002), and addition of metformin in July 2002 led to further improvement (A1c 6.6%) despite a 15-lb weight gain to 190 lb over that time. After administration of metformin, serum TSH fell from 1.30 to 0.14 IU/ml over a 6-month period despite a reduction in the dose of l-T 4 (from 125 g daily to 125 g 6 d/wk or 107 g daily average). A premetformin fT4 was not obtained. Serum fT4 fell during metformin treatment from 1.65 to 1.06 ng/dl ( Table 2) .
Patient 4 is a 75-yr-old woman treated with l-T 4 175 g daily for many years after hypothyroidism developed after a thyroidectomy for papillary thyroid cancer 50 yr previously. She also has hypertension and osteoarthritis. Her other medications were aspirin, calcium, verapamil, hydrochlorothiazide, gabapentin, lisinopril, and furosemide. After diagnosis of type 2 diabetes mellitus in 1998, treatment with insulin was initiated, resulting in moderate control (A1c 7.6%). Addition of metformin XR (500 mg daily) in February 2003, did not improve glycemic control (A1c 8.5% after 3 months) but was associated with a fall in serum TSH from 1.91 to 0.39 IU/ml over 3 months. Five and 14 wk after discontinuation of metformin, serum TSH increased to 0.54 and 1.17 IU/ml, respectively. The patient's weight did not change while on metformin.
Metformin addition to normal serum
When metformin was added to normal serum whose baseline serum TSH was 1.20 IU/ml, the serum TSH concentration varied from 1.06 to 1.20 U/ml.
Results and Discussion
All four hypothyroid patients described in this report had decreases in serum TSH to subnormal levels after the administration of metformin. We are unaware that this finding has been previously reported. By contrast, Oleandri et al. (2) found no differences in thyroid function tests among 28 patients with no known thyroid disease who were treated for obesity with short-acting metformin (500 mg twice daily), dexfenfluramine, or placebo for 3 months in a randomized, controlled trial; weight loss was similar in each group.
Generally, serum TSH levels in a patient on a stable dose of l-T 4 change only when there is a change in absorption, alteration in the dose (or brand) or its bioavailability, a substantial change in weight, or variability in compliance. Reciprocal changes in T 4 levels are usually seen in these circumstances. In patient 1, however, marked changes in serum TSH to subnormal levels were observed without any reciprocal change in serum thyroid hormone levels. In the other three patients, a baseline fT4 was not available. However, TSH remained suppressed in patients 2 and 3 despite lower doses of l-T 4 and lower fT4 levels. These observations were not due to interference in the TSH assay because metformin did not change the TSH value when added to normal serum in concentrations up to 40 times higher than the therapeutic range.
There are several possible mechanisms for the metformininduced TSH suppression in our patients, but these should be considered speculative at the present time. Metformin may have changed the affinity and/or number of thyroid hormone receptors, increased dopaminergic tone, or induced constituent activation of the TSH receptor. These hypotheses would require that metformin be able to cross the bloodbrain barrier. Although metformin is a low-molecular-mass, water-soluble molecule (168 Da), its penetration of the bloodbrain barrier has not been studied. The mechanism of action of metformin at a cellular level is not completely understood but is likely to be multifactorial (3) (4) (5) . The mechanism of thyroid hormone action has been better defined and is quite complex (6) . Whether metformin may affect any of the steps in thyroid hormone action that have been defined to date remains to be determined.
If metformin produced subtle increases in the absorption of l-T 4 from the gastrointestinal tract, then suppression of serum TSH might be predicted. However, we believe that this is unlikely because there was no increase in serum thyroid hormone levels in our most completely studied subject (patient 1). Furthermore, whereas metformin inhibits the absorption of vitamin B12 and folate (7, 8) , it is not known to increase the absorption of nutrients or medications. We cannot exclude the possibility that the TSH suppression in our patients was the result of a subtle, sustained increase in T 4 absorption and consequent rise in free serum thyroid hormone levels that was too small to be detected. In our small retrospective case series, such factors as interassay variation, biological variability of T 4 absorption, or changes in the volume of distribution may have contributed to our findings.
Could our findings be explained by a metformin-induced change in the bioavailability of circulating thyroid hormones? In some circumstances the free fraction of circulating hormones may not be the same as the level of bioavailable hormones in the circulation, e.g. both the free testosterone and non-SHBG-bound testosterone are bioavailable and the combination of both best correlates with the clinical state of the patient (9, 10) . It is of interest in this regard that hormone transport proteins, such as transthyretin, facilitate the passage of T 4 across the cellular barrier, specifically the bloodbrain barrier in the choroid plexus (11, 12) .
In summary, we report four patients in whom metformin appeared to suppress serum TSH to subnormal levels without resulting in biochemical or clinical hyperthyroidism. If our findings are verified and the effect of metformin is central and not peripheral, metformin could be used as an adjunct for the treatment of patients with thyroid cancer because it appears to suppress serum TSH without causing biochemical hyperthyroxinemia or clinical hyperthyroidism.
